[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627461":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":30,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Fondazione IRCCS Policlinico San Matteo di Pavia","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Mario Nuvolone, MD","CONTACT","0382502935","m.nuvolone@smatteo.pv.it",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Fondazione IRCCS Policlinico San Matteo","RECRUITING","Pavia","27100","Italy",{"type":22,"coordinates":23},"Point",[24,25],9.15917,45.19205,{"lat":25,"lon":24},[28],{"name":29,"role":11,"phone":12,"phoneExt":7,"email":13},"Mario Nuvolone",{"type":31,"investigatorFullName":29,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100627461",false,"NCT07448935","One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS","ALPS","Inclusion Criteria:\n\n* Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma\n* Planned peripheral blood sampling +\u002F- bone marrow aspiration\n* Age \\> 18 years\n* Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.\n\nExclusion Criteria:\n\n* Undefined monoclonal gammopathy or non-AL amyloidosis\n* Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy\n* Age \\\u003C18 years\n* Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.","ALL","18 Years","99 Years",{"count":43,"type":44},100,"ESTIMATED","OBSERVATIONAL","By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.",[48,49,50],"AL Amyloidosis","POEMS Syndrome","Multiple Myeloma","2026-04-30",{"date":53,"type":54},"2026-05-06","ACTUAL",{"date":56,"type":54},"2025-11-28",{"date":58,"type":44},"2026-06-30",{"name":5,"class":6},1]